Adherence to the components of the fleetwood model: Self-reported process measures in the Fleetwood Phase III study

Consultant Pharmacist

Volumn 21, Issue 12, 2006, Pages 981-987

  Lapane, Kate L ^a,c   Hughes, Carmel M ^b  

^a BROWN UNIVERSITY   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c BROWN UNIVERSITY   (United States)

Author keywords

Consultant pharmacist; Drug regimen review; Fleetwood model; Geriatrics; Nursing facility; Pharmacy practice

Indexed keywords

AGED; ARTICLE; CONSULTATION; GERIATRIC CARE; HEALTH CARE PLANNING; HIGH RISK PATIENT; HUMAN; MODEL; NURSING HOME; NURSING HOME PATIENT; PATIENT CARE; PHARMACIST; PHARMACY; PHYSICIAN; PROFESSIONAL PRACTICE; SELF REPORT; TEAMWORK;

EID: 33845681694     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2006.981     Document Type: Article

References (7)

1. Hughes CM, Lapane KL. Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes. How successful have they been? Drugs Aging 2005;22:339-51.
2. Office of the Inspector General, Prescription Drug Use in Nursing Homes. In Report 2: An Inside View by Consultant Pharmacists. Washington, DC: Department of Health and Human Services; 1997.
3. Cameron K, Feinberg JL, Lapane KL. Fleetwood project phase III moves forward. Consult Pharm 2002;17:180-200.
4. Lapane KL, Hughes CM. Pharmaceutical care interventions undertaken by pharmacists in the Fleetwood phase III study: the role of process control. Ann Pharmacother 2006; Aug 1 Epub.
5. Lapane KL, Hughes CM, Hiris J et al. Is the use of clinical informatics feasible to exchange information among pharmacists providing care for nursing home residents? [Unpublished].
6. Lapane KL, Hughes CM. Identifying nursing home residents at high-risk for preventable adverse drug events: modifying a tool for use in the Fleetwood phase III study. Consult Pharm 2004;19:533-7.
7. Weinberger M, Murray MD, Marrero DG et al. Effectiveness of pharmacist care for patients with reactive airways disease. JAMA 2002;288:1594-602.